Skip to main content
SpringerLink
Log in

Clinical Perspective: Statins and the Liver—Harmful or Helpful?

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Accessed at: www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Posted Feb 28, 2012.

  2. FDA Consumer Alert: Statins and HIV or Hepatitis C Drugs: drug safety communication—interaction increases risk of muscle injury. Accessed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm294294.htm, Posted March 1, 2012.

  3. FDA Consumer Alert: Important information about interactions between certain hepatitis C drugs and cholesterol-lowering statin drugs. Accessed at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm294485.htm. Posted March 2, 2012.

  4. Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89–93.

    Article  PubMed  Google Scholar 

  5. Bergmann OM, Kristjansson G, Jonasson JG, Bjornsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-011-1950-1.

  6. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.

    Article  PubMed  Google Scholar 

  7. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89:1374–1380.

    Article  PubMed  CAS  Google Scholar 

  8. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62–65.

    Article  PubMed  Google Scholar 

  9. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662–669.

    Article  PubMed  CAS  Google Scholar 

  10. Onusko E. Statins and elevated liver tests: what’s the fuss? J Fam Pract. 2008;57:449–452.

    PubMed  Google Scholar 

  11. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105:978–980.

    Article  PubMed  Google Scholar 

  12. Bader T. Liver tests are irrelevant when prescribing statins. Lancet. 2010;376:1882–1883.

    Article  PubMed  Google Scholar 

  13. Bader T. Yes! Statins can be given to liver patients. J Hepatol. 2012;56:305–307.

    Article  PubMed  Google Scholar 

  14. Cohen DE, Anania FA, Chalasani N, The National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:S77–S81.

    Google Scholar 

  15. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412–422.

    Article  PubMed  CAS  Google Scholar 

  16. Athyros VG, Tziomalos K, Gossios T, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests; in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post hoc analysis. Lancet. 2010;376:1916–1922.

    Article  PubMed  CAS  Google Scholar 

  17. Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26:338–341.

    Article  PubMed  Google Scholar 

  18. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1563.

    Article  PubMed  CAS  Google Scholar 

  19. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349–356.

    Article  PubMed  Google Scholar 

  20. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272–278.

    Article  PubMed  Google Scholar 

  21. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme a reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol. 2011;5:450–459.

    Article  PubMed  Google Scholar 

  22. Tolman K. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85:15E–19E.

    Article  PubMed  CAS  Google Scholar 

  23. Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf. 2008;31:325–334.

    Article  PubMed  Google Scholar 

  24. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695.

    Article  PubMed  CAS  Google Scholar 

  25. Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–1101.

    Article  PubMed  Google Scholar 

  26. Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33–38.

    Article  PubMed  Google Scholar 

  27. Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther. 1989;248:498–505.

    PubMed  CAS  Google Scholar 

  28. Horsmans Y, DeSager JP, Harveng TC. Biochemical changes and morphological alterations of the liver in guinea pigs after administration of simvastatin HMG-CoA reductase-inhibitor. Pharmacol Toxicol. 1990;67:336–339.

    Article  PubMed  CAS  Google Scholar 

  29. Zimmerman HJ. The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:662.

    Google Scholar 

  30. Tavintharan S, Ong CN, Jeyaseelan K, et al. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol. 2007;223:173–179.

    Article  PubMed  CAS  Google Scholar 

  31. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–2237.

    Article  PubMed  CAS  Google Scholar 

  32. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13:76–79.

    Article  PubMed  Google Scholar 

  33. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–2797.

    Article  PubMed  CAS  Google Scholar 

  34. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24:584–591.

    Article  PubMed  Google Scholar 

  35. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation. 2002;105:2341–2346.

    Article  PubMed  CAS  Google Scholar 

  36. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  37. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618–624.

    Article  PubMed  CAS  Google Scholar 

  38. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing Database. Liver Transpl. 2009;15:719–729.

    Article  PubMed  Google Scholar 

  39. Reuben A, Koch DG, Lee WM, The Acute Liver Failure Study Group. Drug-induced acute liver failure: results of an US Multicenter, prospective study. Hepatology. 2010;52:2065–2076.

    Google Scholar 

  40. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.

    PubMed  Google Scholar 

  41. Björnsson E, Olsson R. Outcome and prognostic markers in sever drug-induced liver disease. Hepatology. 2005;42:481–489.

    Article  PubMed  Google Scholar 

  42. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single center experience with drug-induced liver injury from India: Causes, outcomes, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404.

    Article  PubMed  Google Scholar 

  43. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934.

    Article  PubMed  Google Scholar 

  44. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research, vol. 6. New York: Raven Press; 1984:1–7.

    Google Scholar 

  45. Davern TJ, Chalasani N, Fontana RJ, et al. Acute Hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.

    Article  PubMed  Google Scholar 

  46. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429–1435.

    Article  PubMed  CAS  Google Scholar 

  47. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275–1311.

    Google Scholar 

  48. Lewis JH. Liver disease caused by anesthetics, toxins, and herbal preparations. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Diseases. Pathophysiology/Diagnosis/Management. 9th edition. 2010;1447–1476.

  49. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.

    Article  PubMed  CAS  Google Scholar 

  50. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.

    Article  PubMed  CAS  Google Scholar 

  51. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463–470.

    Article  PubMed  Google Scholar 

  52. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.

    Article  PubMed  Google Scholar 

  53. Lewis JH. Liver biopsy differentiates DILI from autoimmune hepatitis. Nature Rev Gastroenterol Hepatol. 2011;8:540–542.

    Article  Google Scholar 

  54. Lewis JH, Kleiner D. Hepatic Injury due to Drugs, herbal compounds, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween’s Pathology of the Liver. 6th ed. Edinburgh: Churchill Livingstone Elsevier; 2012:645–760.

    Chapter  Google Scholar 

  55. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: Promises and pitfalls. Clin Liver Dis. 2007;11:477–505.

    Article  PubMed  Google Scholar 

  56. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.

    Article  PubMed  Google Scholar 

  57. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319:1541.

    Article  PubMed  CAS  Google Scholar 

  58. Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.

    PubMed  Google Scholar 

  59. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33:308–310.

    Article  PubMed  CAS  Google Scholar 

  60. Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100:295–298.

    Article  PubMed  CAS  Google Scholar 

  61. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82:392–406.

    Article  Google Scholar 

  62. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28:351–370.

    Article  PubMed  CAS  Google Scholar 

  63. Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf causality assessment method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther. 2008;46:327–339.

    PubMed  CAS  Google Scholar 

  64. Friis RH, Sellers TA. Epidemiology for Public Health Practice. Sudbury, MA: Jones & Bartlett Learning 2009:93–140.

  65. Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet. 2002;359:853–854.

    Article  PubMed  CAS  Google Scholar 

  66. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902–907.

    Article  PubMed  CAS  Google Scholar 

  67. Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007;27:845–851.

    Article  PubMed  CAS  Google Scholar 

  68. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010;55:190–195.

    Article  PubMed  CAS  Google Scholar 

  69. Madhoun MF, Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci. 2010;55:870–871.

    Article  PubMed  Google Scholar 

  70. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52:864–874.

    Article  PubMed  CAS  Google Scholar 

  71. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006;44:335–340.

    Article  PubMed  CAS  Google Scholar 

  72. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol. 2007;46:411–419.

    Article  PubMed  CAS  Google Scholar 

  73. Amemiya F, Maekawa S, Itakura Y, et al. Tageting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis. 2008;197:361–370.

    Article  PubMed  CAS  Google Scholar 

  74. Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–125.

    Article  PubMed  CAS  Google Scholar 

  75. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci. 2007;105:145–150.

    Article  PubMed  CAS  Google Scholar 

  76. Delang L, Paeshuvse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatolohy. 2009;50:6–16.

    Article  CAS  Google Scholar 

  77. Mihaila R, Nedelcu L, Fratila O, et al. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology. 2009;56:1704–1709.

    PubMed  CAS  Google Scholar 

  78. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat. 2009;16:479–484.

    Article  PubMed  CAS  Google Scholar 

  79. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103:1383–1389.

    Article  PubMed  CAS  Google Scholar 

  80. Rao GA, Pandva PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology. 2011;140:144–152.

    Article  PubMed  CAS  Google Scholar 

  81. Shimada M, Yoshida S, Masuzaki R, Schuppan D. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. J Hepatol. 2012;56:298–302.

    Article  Google Scholar 

  82. Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 2010;86:241–245.

    Article  PubMed  CAS  Google Scholar 

  83. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.

    Article  PubMed  CAS  Google Scholar 

  84. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  85. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–1608.

    Article  PubMed  CAS  Google Scholar 

  86. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B infection. J Clin Oncol. 2012;30:623–630.

    Google Scholar 

  87. Zhang W, Wu J, Zhou L, Xie HY, Zheng SS. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010;48:1167–1174.

    PubMed  CAS  Google Scholar 

  88. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26:735–741.

    Article  PubMed  CAS  Google Scholar 

  89. Relja B, Meder F, Wang M, et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011;38:879–885.

    Google Scholar 

  90. Popovich DG, Tiaras F, Yeo CR, Zhang W. Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth. Am Coll Nutr. 2010;29:204–210.

    CAS  Google Scholar 

  91. Dold S, Laschke MW, Lavasani S, et al. Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol. 2009;156:466–474.

    Article  PubMed  CAS  Google Scholar 

  92. Demirbilek S, Tas E, Gurunluoglu K, et al. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Ped Surg Int. 2007;23:155–162.

    Article  Google Scholar 

  93. Russo L, Gracia-Sancho J, García-Calderó H, et al. Addition of simvastatin to cold storage prevents endothelial dysfunction in explanted rat livers. Hepatology. 2012;55:921–930.

    Article  PubMed  CAS  Google Scholar 

  94. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831–833.

    Article  PubMed  CAS  Google Scholar 

  95. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. 2004;94:30F–34F.

    Article  PubMed  CAS  Google Scholar 

  96. Leaver H. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther. 2009;27:96–100.

    Article  PubMed  Google Scholar 

  97. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C–94C.

    Google Scholar 

  98. Ward S. A systemic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.

    Google Scholar 

  99. Mac Carthy EP. Important Drug Warning. Market withdrawal of Baycol (cervistatin). Bayer Corporation, West Haven, CT. August 8, 2001.

  100. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;22:441–457.

    Google Scholar 

  101. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280–288.

    Article  PubMed  CAS  Google Scholar 

  102. Conforti A, Magro L, Moretti U, et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf. 2006;29:1163–1172.

    Article  PubMed  CAS  Google Scholar 

  103. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in Swedish University Hospital Outpatient Hepatology Clinic. Aliment Pharmacol Ther. 2006;24:1187–1195.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Georgetown University Medical Center, Washington, DC, USA

    James H. Lewis

Authors
  1. James H. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James H. Lewis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewis, J.H. Clinical Perspective: Statins and the Liver—Harmful or Helpful?. Dig Dis Sci 57, 1754–1763 (2012). https://doi.org/10.1007/s10620-012-2207-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2207-3

Keywords

Search

Navigation